Immunogenic cell death‐inducing small molecule inhibitors: Potential for immunotherapy of cancer

Abstract

Abstract Small molecule inhibitors (SMIs) of key signalling pathways are known to induce multiple types of regulated cell death, including immunogenic cell death (ICD). The resulting antitumor immunity helps to overcome the resistance of cancer cells to cell death, resulting in improved cancer therapy. SMIs, especially those inducing multimodal cell death and ICD, can be critical components in rational combinations for cancer immunotherapy.